Immune response after vaccination of HIV infected individuals receiving HAART with overlapping gag peptides pulsed on autologous cells

Immune response after vaccination of HIV infected individuals receiving HAART with overlapping gag peptides pulsed on autologous cells

Bibliographic Details
Main Authors:	Kloverpris, H, Jackson, A, Handley, A, Hayes, P, Gilmour, J, Atkins, M, Walker, B, Ackland, J, Sullivan, M, Goulder, P
Format:	Journal article
Published:	2012

Similar Items

Non-immunogenicity of overlapping gag peptides pulsed on autologous cells after vaccination of HIV infected individuals.
by: Henrik N Kløverpris, et al.
Published: (2013-01-01)

A first-in-man, double blind, placebo controlled study of the candidate therapeutic vaccine Opal-HIV-Gag(c) in HIV infected patients receiving HAART
by: Jackson AG, et al.
Published: (2012-09-01)

A randomised, placebo-controlled, first-in-human study of a novel clade C therapeutic peptide vaccine administered ex vivo to autologous white blood cells in HIV infected individuals.
by: Akil Jackson, et al.
Published: (2013-01-01)

Dimethyl sulfoxide (DMSO) exposure to human peripheral blood mononuclear cells (PBMCs) abolish T cell responses only in high concentrations and following coincubation for more than two hours.
by: Kloverpris, H, et al.
Published: (2010)

Early presentation of HIV-1 KF11Gag and KK10Gag protective epitopes facilitate rapid CD8+T cell activation and killing of virus infected cells
by: Kloverpris, H, et al.
Published: (2012)

Early antigen presentation of protective HIV-1 KF11Gag and KK10Gag epitopes from incoming viral particles facilitates rapid recognition of infected cells by specific CD8+ T cells.
by: Kløverpris, H, et al.
Published: (2013)

HIV-1 Escape from an HLA-B*13-Restricted Gag Epitope Affects the Gag-Pol Frameshift Stem-loop and Reduces Viral Fitness
by: Prado, J, et al.
Published: (2008)

HLA-A*68:02-restricted Gag-specific cytotoxic T lymphocyte responses can drive selection pressure on HIV but are subdominant and ineffective.
by: Kløverpris, H, et al.
Published: (2013)

HLA-A*68: 02-restricted Gag-specific cytotoxic T lymphocyte responses can drive selection pressure on HIV but are subdominant and ineffective
by: Kløverpris, H, et al.
Published: (2013)

Important contribution of p15 Gag-specific responses to the total Gag-specific CTL responses.
by: Yu, X, et al.
Published: (2002)

Immunodominant Anti-Gag SLYNTVATL Responses in HIV-patients With More Than Five Years of HAART-induced Undetectable Plasma Viremia
by: Gagro Alenka, et al.
Published: (2005-12-01)

Dynamics and frequency of Gag transmitted polymorphisms in Zambia
by: Schaefer, M, et al.
Published: (2012)

Dynamics and frequency of Gag transmitted polymorphisms in Zambia
by: Schaefer M, et al.
Published: (2012-09-01)

Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells.
by: Payne, R, et al.
Published: (2010)

Impact of immune-driven sequence variation in HIV-1 subtype C Gag-Protease on viral fitness and disease progression
by: Wright, J, et al.
Published: (2009)

Neurodegeneration in the HAART era
by: Brew Bruce J
Published: (2010-05-01)

Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag.
by: Carlson, J, et al.
Published: (2008)

Broad and Gag-biased HIV-1 epitope repertoires are associated with lower viral loads.
by: Rolland, M, et al.
Published: (2008)

New Insights Into Retroviral Gag-Gag and Gag-Membrane Interactions
by: Jose eMaldonado, et al.
Published: (2014-06-01)

P09-09. Impact of immune-driven sequence variation in HIV-1 subtype C Gag-Protease on viral fitness and disease progression
by: Wright, J, et al.
Published: (2009)

Metabolic profile and cardiovascular risk factors among Latin American HIV-infected patients receiving HAART
by: P. Cahn, et al.
Published: (2010-03-01)

Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses.
by: Julg, B, et al.
Published: (2010)

Metabolic profile and cardiovascular risk factors among Latin American HIV-infected patients receiving HAART
by: P Cahn, et al.

HAART and the liver: friend or foe?
by: Pineda JA, et al.
Published: (2010-03-01)

Determinants of survival following HIV-1 seroconversion after the introduction of HAART.
by: Porter, K, et al.
Published: (2003)

Gag-Gag Interactions Are Insufficient to Fully Stabilize and Order the Immature HIV Gag Lattice
by: Ipsita Saha, et al.
Published: (2021-09-01)

HIV/HCV coinfection, HAART, and liver-related mortality.
by: Sabin, C, et al.
Published: (2004)

Hypertension among HIV-infected adults receiving highly active antiretroviral therapy (HAART) in Malaysia
by: Hejazi, Nazisa, et al.
Published: (2014)

Impact of HLA-B*81-associated mutations in HIV-1 Gag on viral replication capacity.
by: Wright, J, et al.
Published: (2012)

Mosaic HIV-1 Gag antigens can be processed and presented to human HIV-specific CD8+ T cells.
by: Ndhlovu, Z, et al.
Published: (2011)

Polyvalent Gag-specific CD8 T-cells with enhanced functional properties are enriched in HIV-1 clade C infected individuals with lower viral loads
by: Julg, B, et al.
Published: (2009)

Cw*0303/0304 HIV specific CTL response toward GagYL9 select for HIV escape variants with low fitness that is compensated by intra-codon variation
by: Honeyborne, I, et al.
Published: (2009)

pTHr.HIVA and MVA.HIVA vaccines (gag p24/p17) augment CD4+T cell responses in chronically infected HIV-1 patients on HAART
by: Ondondo, B, et al.
Published: (2005)

Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag.
by: Jonathan M Carlson, et al.
Published: (2008-11-01)

Chemoprophylaxis and HAART Therapy in Botswana
by: Essex M
Published: (2005-12-01)

517 IN VITRO: GENE EXPRESSION OF GAG SYNTHESIZING GENES IN RELATION TO GAG-THERAPY.
by: C Van Ginkel, et al.
Published: (2022-06-01)

A decade of HAART in Latin America: Long term outcomes among the first wave of HIV patients to receive combination therapy.
by: Marcelo J Wolff, et al.
Published: (2017-01-01)

Impact of intrapeptide epitope location on CD8 T cell recognition: implications for design of overlapping peptide panels.
by: Draenert, R, et al.
Published: (2004)

Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1.
by: Martinez-Picado, J, et al.
Published: (2006)

Identification of a novel HLA-B*3501-restricted cytotoxic T lymphocyte epitope using overlapping peptides.
by: Goulder, P, et al.
Published: (1997)